Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest oncology group/Eastern cooperative oncology group study

Blood

Volumn 96, Issue 13, 2000, Pages 4075-4083

  Slovak, Marilyn L ^a   Kopecky, Kenneth J ^a   Cassileth, Peter A ^a   Harrington, David H ^a   Theil, Karl S ^a   Mohamed, Anwar ^a   Paietta, Elizabeth ^a   Willman, Cheryl L ^a   Head, David R ^a   Rowe, Jacob M ^a   Forman, Stephen J ^a   Appelbaum, Frederick R ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; IDARUBICIN;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ANEUPLOIDY; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE TRANSLOCATION; GENETICS; HUMAN; HUMAN CHROMOSOME; KARYOTYPING; LIFE TABLE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK; SURVIVAL; TREATMENT OUTCOME; ULTRASTRUCTURE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANEUPLOIDY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; COMBINED MODALITY THERAPY; CYTARABINE; FEMALE; HUMANS; IDARUBICIN; KARYOTYPING; LEUKEMIA, MYELOID; LIFE TABLES; MALE; MIDDLE AGED; REMISSION INDUCTION; RISK; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0034672269     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.13.4075     Document Type: Article

References (17)

1. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24: 17-31.
2. Raimondi SC, Ravindranath Y, Chang MN, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study - POG 8821. Blood. 1999; 94:3707-3716.
3. Tallman M, Andersen JW, Schiffer CA, et al. Alltrans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
4. Fenaux P, Chomienne C, Degos L. Acute promyelocytic leukemia: biology and treatment. Semin Oncol.1997;24:92-102.
5. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
6. Buchner T, Hiddemann W. Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood.1999;93:4116-4124.
7. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med. 1995;332: 217-223.
8. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 1997;90:2978-2986.
9. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.
10. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRCAML 10 trial. Blood. 1998;92:2322-2333.
11. Mitelman F, ed. ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel: S. Kargen 1995.
12. Slovak ML, Traweek ST, Willman CL, et al. Trisomy 11: an association with stem/progenitor cell immunophenotype. Br J Haematol. 1995:90:266-273.
13. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia. 1995;9:1491-1498.
14. Behm FG, Raimondi SC, Frestedt JL, et al. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood. 1996;87: 2870-2877.
15. Schoch C, Haase D, Hafertach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22:q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996; 10:1288-1295.
16. Alsabeh R, Brynes RK, Slovak ML, Arber DA. Acute myeloid leukemia with t(6;9)(p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol. 1997;107:430-437.
17. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8: 813-819.